iCardiac Launches Newly Named “PFT Global” Service Line, Completing Post-Merger Integration
The move rebrands the respiratory services acquired by iCardiac and reflects enhanced capabilities
March 22, 2016, Rochester, NY - iCardiac Technologies, Inc., a market leader in the conduct of respiratory and cardiac safety studies, today unveiled “PFT Global”, the new name of its respiratory testing service line. The move completes a six-month process of integrating the clinical trials division of nSpire Health, which was acquired in July 2015, into the iCardiac organization. It also reflects the broader respiratory service capabilities that were enabled by the acquisition.
The newly named PFT Global service line continues to be a leader in respiratory clinical research, having captured over 10 million pulmonary function tests worldwide over the past 10 years and supporting research sites in over 60 countries. The business is focused on supporting clinical trials in Phase II and III. This includes study sizes ranging from two sites and 50 patients to global-scale pivotal projects covering 30 countries with 750 clinical sites and 14,000 subjects.
“This renaming was the culmination of our comprehensive efforts to integrate our acquired respiratory services into iCardiac,” said John Sage, Senior Vice President of Respiratory and ePRO at iCardiac. “As a result of the integration, our sponsors will benefit from various enhanced capabilities, including our broader capacity and resources in relation to project management, site support, and global logistics.”
“This new name of our respiratory service line represents a company milestone and symbolizes what we offer to sponsors,” said Alex Zapesochny, President and CEO of iCardiac. “Over the years we have become a company with superb global capabilities, and we offer an expertise in pulmonary function testing that is second to none.”
About iCardiac Technologies:
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for respiratory and cardiac safety services. Its high precision cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit: www.icardiac.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
